Schedule 13G ownership disclosure
CRISPR Therapeutics AG
COMMON STOCK · CUSIP: H17182108
Event date: 2026-09-30
- Filing-level shares
- 4,994,047.00
- Percent of class
- 5.2%
- STATE STREET CORPORATION
Shares: 4,994,047.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000093751-26-000637
- Form type
- SCHEDULE 13G
- Filer
- CRISPR Therapeutics AG
- CIK
- CIK 1674416
- Filed
- Nov 10, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership